Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by jfm1330


T.TH

RE:RE:RE:RE:RE:Trial with unique way to deliver Docetaxel

On the website of the company it is stated that the linker is not cleaved...

July 3, 2021

T.TH

RE:Trial with unique way to deliver Docetaxel

Here is the link to the website of the company behind this micelle approach...

July 3, 2021

T.TH

RE:RE:RE:RE:Trial with unique way to deliver Docetaxel

I read the article. Some interesting points. First, they use a linker to...

July 3, 2021

T.TH

RE:RE:RE:RE:Trial with unique way to deliver Docetaxel

The therapeutic window, or therapeutic index is the interval between the...

July 3, 2021

T.TH

Pharmacokinetics and the fate of TH1902 in the body

This is one area where Thera did not disclosed much data obtained on animals...

July 2, 2021

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

Obviously, both are possible, that's the beauty of a drug with a large...

July 1, 2021

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

Marsolais said that reaching MTD at the begining of the fall is possible. So...

July 1, 2021

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

Obviously I meant several phase IIa, so testing on many types of cancer at...

July 1, 2021

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

I listened again to the presentation part on toxicity and dose escalation...

July 1, 2021

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

Remember that if the MTD ends up being very high, like three times MTD of...

July 1, 2021

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

Marsolais said during the presentation that if there is efficacy in part I of...

July 1, 2021

T.TH

RE:Speculating about the next financing

This sums up the situation pretty well. And from now on, the more we don'...

July 1, 2021

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:Fitting

For a very effective cancer drug, the path to approval can be pretty quick. A...

July 1, 2021

T.TH

RE:RE:International preclinical project Managet

It looks like they are already planning new PDCs that will require...

June 29, 2021

T.TH

RE:RE:Interesting conversation

As I explained it here before, to me melphalan fluferamide (Melflufen) is not...

June 29, 2021

T.TH

RE:RE:RE:Where things are at

They already published that in IND enabling toxicity study they were able to...

June 28, 2021

T.TH

RE:RE:RE:Clear proof of concept is the key

Every iteration of the peptide + cancer drug becomes a new chemical entity...

June 27, 2021

T.TH

RE:RE:Clear proof of concept is the key

They will likely need to follow the same process every times if they ever...

June 27, 2021

T.TH

Clear proof of concept is the key

If they can come up with clear efficacy results, the stock price will rise...

June 27, 2021

T.TH

RE:Lutetium in NYTimes this morning

Wino, It targets a protein, not a gene. It would be very easy to attach...

June 25, 2021

Featured Company